rs4143815-<i>PDL1</i>, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy
Up to 30−50% of patients with locally advanced prostate cancer (PCa) undergoing radiotherapy (RT) experience biochemical recurrence (BCR). The immune system affects the RT response. Immunogenetics could define new biomarkers for personalization of PCa patients’ treatment. The aim...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/9/2082 |
id |
doaj-ed278f9d892d4fe28ba95713f60182f7 |
---|---|
record_format |
Article |
spelling |
doaj-ed278f9d892d4fe28ba95713f60182f72020-11-25T00:52:33ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-04-01209208210.3390/ijms20092082ijms20092082rs4143815-<i>PDL1</i>, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after RadiotherapyChiara Zanusso0Eva Dreussi1Roberto Bortolus2Chiara Romualdi3Sara Gagno4Elena De Mattia5Loredana Romanato6Franca Sartor7Luca Quartuccio8Erika Cecchin9Giuseppe Toffoli10Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyDepartment of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyDepartment of Biology, University of Padova, 35122 Padova, ItalyExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyRheumatology Clinic, Department of Medical and Biological Sciences, University Hospital “Santa Maria della Misericordia”, 33100 Udine, ItalyExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyExperimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, ItalyUp to 30−50% of patients with locally advanced prostate cancer (PCa) undergoing radiotherapy (RT) experience biochemical recurrence (BCR). The immune system affects the RT response. Immunogenetics could define new biomarkers for personalization of PCa patients’ treatment. The aim of this study is to define the immunogenetic biomarkers of 10 year BCR (primary aim), 10 year overall survival (OS) and 5 year BCR (secondary aims). In this mono-institutional retrospective study, 549 Caucasian patients (a discovery set <i>n</i> = 418; a replication set <i>n</i> = 131) were affected by locally advanced PCa and homogeneously treated with RT. In the training set, associations were made between 447 SNPs in 77 genes of the immune system; and 10 year BCR and 10 year OS were tested through a multivariate Cox proportional hazard model. Significant SNPs (<i>p</i>-value < 0.05, <i>q</i>-value < 0.15) were analyzed in the replication set. Replicated SNPs were tested for 5 year BCR in both sets of patients. A polymorphism in the <i>PDL1</i> gene (rs4143815) was the unique potential genetic variant of 10 year BCR (training set: <i>p</i> = 0.003, HR (95% CI) = 0.58 (0.41−0.83); replication set: <i>p</i> = 0.063, HR (95% CI) = 0.52 (0.26−1.04)) that was significantly associated with 5 year BCR (training set: <i>p</i> = 0.009, HR (95% CI) = 0.59 (0.40−0.88); replication set: <i>p</i> = 0.036, HR (95% CI) = 0.39 (0.16−0.94)). No biomarkers of OS were replicated. rs4143815-<i>PDL1</i> arose as a new immunogenetic biomarker of BCR in PCa, giving new insights into the RT/immune system interaction, which could be potentially useful in new approaches using anti-PDL1 therapies for PCa.https://www.mdpi.com/1422-0067/20/9/2082prostate cancerimmunogeneticsbiomarkerradiotherapybiochemical recurrence |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chiara Zanusso Eva Dreussi Roberto Bortolus Chiara Romualdi Sara Gagno Elena De Mattia Loredana Romanato Franca Sartor Luca Quartuccio Erika Cecchin Giuseppe Toffoli |
spellingShingle |
Chiara Zanusso Eva Dreussi Roberto Bortolus Chiara Romualdi Sara Gagno Elena De Mattia Loredana Romanato Franca Sartor Luca Quartuccio Erika Cecchin Giuseppe Toffoli rs4143815-<i>PDL1</i>, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy International Journal of Molecular Sciences prostate cancer immunogenetics biomarker radiotherapy biochemical recurrence |
author_facet |
Chiara Zanusso Eva Dreussi Roberto Bortolus Chiara Romualdi Sara Gagno Elena De Mattia Loredana Romanato Franca Sartor Luca Quartuccio Erika Cecchin Giuseppe Toffoli |
author_sort |
Chiara Zanusso |
title |
rs4143815-<i>PDL1</i>, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy |
title_short |
rs4143815-<i>PDL1</i>, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy |
title_full |
rs4143815-<i>PDL1</i>, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy |
title_fullStr |
rs4143815-<i>PDL1</i>, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy |
title_full_unstemmed |
rs4143815-<i>PDL1</i>, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy |
title_sort |
rs4143815-<i>pdl1</i>, a new potential immunogenetic biomarker of biochemical recurrence in locally advanced prostate cancer after radiotherapy |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2019-04-01 |
description |
Up to 30−50% of patients with locally advanced prostate cancer (PCa) undergoing radiotherapy (RT) experience biochemical recurrence (BCR). The immune system affects the RT response. Immunogenetics could define new biomarkers for personalization of PCa patients’ treatment. The aim of this study is to define the immunogenetic biomarkers of 10 year BCR (primary aim), 10 year overall survival (OS) and 5 year BCR (secondary aims). In this mono-institutional retrospective study, 549 Caucasian patients (a discovery set <i>n</i> = 418; a replication set <i>n</i> = 131) were affected by locally advanced PCa and homogeneously treated with RT. In the training set, associations were made between 447 SNPs in 77 genes of the immune system; and 10 year BCR and 10 year OS were tested through a multivariate Cox proportional hazard model. Significant SNPs (<i>p</i>-value < 0.05, <i>q</i>-value < 0.15) were analyzed in the replication set. Replicated SNPs were tested for 5 year BCR in both sets of patients. A polymorphism in the <i>PDL1</i> gene (rs4143815) was the unique potential genetic variant of 10 year BCR (training set: <i>p</i> = 0.003, HR (95% CI) = 0.58 (0.41−0.83); replication set: <i>p</i> = 0.063, HR (95% CI) = 0.52 (0.26−1.04)) that was significantly associated with 5 year BCR (training set: <i>p</i> = 0.009, HR (95% CI) = 0.59 (0.40−0.88); replication set: <i>p</i> = 0.036, HR (95% CI) = 0.39 (0.16−0.94)). No biomarkers of OS were replicated. rs4143815-<i>PDL1</i> arose as a new immunogenetic biomarker of BCR in PCa, giving new insights into the RT/immune system interaction, which could be potentially useful in new approaches using anti-PDL1 therapies for PCa. |
topic |
prostate cancer immunogenetics biomarker radiotherapy biochemical recurrence |
url |
https://www.mdpi.com/1422-0067/20/9/2082 |
work_keys_str_mv |
AT chiarazanusso rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy AT evadreussi rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy AT robertobortolus rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy AT chiararomualdi rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy AT saragagno rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy AT elenademattia rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy AT loredanaromanato rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy AT francasartor rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy AT lucaquartuccio rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy AT erikacecchin rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy AT giuseppetoffoli rs4143815ipdl1ianewpotentialimmunogeneticbiomarkerofbiochemicalrecurrenceinlocallyadvancedprostatecancerafterradiotherapy |
_version_ |
1725241784889507840 |